The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Patterns of treatment (tx) with bone-modifying agents (BMA) in patients with bone metastases (mets).
Jane M Quigley
Research Funding - Amgen
Rohini Khorana Hernandez
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Karynsa Cetin
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Melissa A. Pirolli
Research Funding - Amgen
David Quach
Research Funding - Amgen
Alexander Liede
Employment or Leadership Position - Amgen
Stock Ownership - Amgen